Meningococcal Disease Vaccines Market Set to Increase Due to Government and Private Healthcare Initiatives

Meningococcal disease is a catastrophic infection that spreads through the Neisseria meningitides bacteria. The disease occurs due to aggravation of the pathogenicity of the bacteria due to seasonal variations and is a life-threatening illness. Meningococcal disease occurs when meninges, the thin lining surrounding the brain and spinal cord, are severely infected. Vaccines for immunization have helped save millions of lives and are considered the most effective method of prevention of many communicable diseases.

Five serogroups of bacteria cause the invasive global meningococcal disease vaccines market. The serogroups mainly exist in humans in a dormant state and eventually cause the disease due to factors such as environment or immunogenic causes. The most prominent serogroups are A, B, C, Y, and W-135. The serogroups occur in variations based on age, geographical locations, and time. The disease can result in death within 24 hours from the onset of symptoms and is contagious. The disease has a high mortality rate and is fatal if not diagnosed or treated.

Browse Full Global Meningococcal Disease Vaccines Market Research Report With Complete TOC @ http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html

Bexsero, Trumenba, NmVac4 DT Vaccines Lead Meningococcal Disease Vaccines Market

Vaccines are the best known preventive measures for meningococcal disease and there are vaccines available for prevention of meningitis, meningococcemia, and septicemia. Bexsero by Novartis and Trumenba by Pfizer are vaccines that have been recently approved in the U.S. in January 2015, and October 2014, respectively. Novartis was allowed to market Bexsero for serogroup B in Europe, Canada, and Australia. NmVac4 DT is a conjugate vaccine against meningococcal disease has been developed against the serogroups A, C, Y and W-135. This vaccine is animal component free, which could increase its demand post launch.

Vaccines for meningococcal disease...